Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority …
GK Rai, T Saluja, S Chaudhary, D Tamrakar… - The Lancet Infectious …, 2022 - thelancet.com
Background Typhoid fever is an endemic disease in many low-income and middle-income
countries. The 2018 WHO position paper recommends that countries should consider …
countries. The 2018 WHO position paper recommends that countries should consider …
A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of VI-diphtheria Toxoid versus VI-tetanus Toxoid …
S Chaudhary, GS Shah, NK Bhatta… - Human Vaccines & …, 2023 - Taylor & Francis
Typhoid remains one of the major serious health concerns for children in developing
countries. With extremely drug-resistant cases emerging, preventative measures like …
countries. With extremely drug-resistant cases emerging, preventative measures like …
[HTML][HTML] Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children
MR Capeding, S Teshome, T Saluja, KA Syed, DR Kim… - Vaccine, 2018 - Elsevier
Background Typhoid fever remains a major public health problem in low-and middle-income
countries where children aged 2–14 years bear the greatest burden. Vi polysaccharide is …
countries where children aged 2–14 years bear the greatest burden. Vi polysaccharide is …
Assessing the impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infection among Bangladeshi children: a protocol for a phase IIIb trial
K Theiss-Nyland, F Qadri, R Colin-Jones… - Clinical Infectious …, 2019 - academic.oup.com
Background Typhoid fever illnesses are responsible for more than 100 000 deaths
worldwide each year. In Bangladesh, typhoid fever is endemic, with incidence rates between …
worldwide each year. In Bangladesh, typhoid fever is endemic, with incidence rates between …
Gateway to Typhoid Conjugate Vaccine Introduction in India and Beyond—Programmatic Effectiveness of a Public Sector Typhoid Conjugate Vaccine Campaign in …
ME Carey - Clinical Infectious Diseases, 2023 - academic.oup.com
(S. Typhi) caused an estimated 9.24 million cases (5.94 M, 14.1 M) of typhoid fever in 2019,
resulting in 110 000 deaths (52 800, 191 000)[1]. Over 4.8 million cases and 50 000 deaths …
resulting in 110 000 deaths (52 800, 191 000)[1]. Over 4.8 million cases and 50 000 deaths …
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial
Background Typhoid fever remains a major cause of morbidity and mortality in low-income
and middle-income countries. Vi-tetanus toxoid conjugate vaccine (Vi-TT) is recommended …
and middle-income countries. Vi-tetanus toxoid conjugate vaccine (Vi-TT) is recommended …
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial
M Shakya, M Voysey, K Theiss-Nyland… - The Lancet Global …, 2021 - thelancet.com
Background Typhoid fever is a major public health problem in low-resource settings.
Vaccination can help curb the disease and might reduce transmission. We have previously …
Vaccination can help curb the disease and might reduce transmission. We have previously …
Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data
Y Liang, AJ Driscoll, PD Patel, S Datta… - The Lancet Global …, 2023 - thelancet.com
Background Typhoid conjugate vaccines are being introduced in low-income and middle-
income countries to prevent typhoid illness in children. Vaccine effectiveness studies assess …
income countries to prevent typhoid illness in children. Vaccine effectiveness studies assess …
A phase II, randomized, double-blind, controlled safety and immunogenicity trial of typhoid conjugate vaccine in children under 2 years of age in Ouagadougou …
MB Laurens, SB Sirima, ET Rotrosen… - Clinical Infectious …, 2019 - academic.oup.com
Abstract The recent Typhoid Fever Surveillance in Africa Program demonstrated an overall
adjusted incidence of typhoid fever 2–3 times higher than previous estimates in Africa …
adjusted incidence of typhoid fever 2–3 times higher than previous estimates in Africa …
Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal
M Shakya, R Colin-Jones… - … England Journal of …, 2019 - Mass Medical Soc
Abstract Background Salmonella Typhi is a major cause of fever in children in low-and
middle-income countries. A typhoid conjugate vaccine (TCV) that was recently prequalified …
middle-income countries. A typhoid conjugate vaccine (TCV) that was recently prequalified …